[][com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=86935]], camposKey:1663-9812 2024-01-01 Ala®sil chemical characterization and toxicity evaluation: an example of the need for the Medical Devices Regulation (MDR) 2017/74500, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=86666]], camposKey:1757-6512 2024-01-01 Clinical exome analysis and targeted gene repair of the c.1354dupT variant in iPSC lines from patients with <i>PROM1</i>-related retinopathies exhibiting diverse phenotypes00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=80421]], camposKey:1757-6512 2023-12-01 Intravitreal allogeneic mesenchymal stem cells: a non-randomized phase II clinical trial for acute non-arteritic optic neuropathy00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=80681]], camposKey:0275-004X 2023-08-01 INTRAOCULAR EMULSION OF SILICONE OIL (ITEMS) GRADING SYSTEM: An Evidence-Based Expert-Led Consensus13701376, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=75910]], camposKey:2077-0383 2023-03-01 Does PLEX® Elite 9000 OCT Identify and Characterize Most Posterior Pole Lesions in Highly Myopic Patients?00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=75707]], camposKey:2077-0383 2023-03-01 Impact of COVID-19 Confinement on Quality of Life of Patients with Age-Related Macular Degeneration: A Two-Wave Panel Study00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=78307]], camposKey:0365-6691 2023-01-01 Evaluación de signos tomográficos no exudativos en casos de degeneración macular asociada a la edad de tipo exudativo276280, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=75911]], camposKey:0365-6691 2023-01-01 Evaluation of non-exudative tomographic signs in cases of exudative age-related macular degeneration Evaluación de signos tomográficos no exudativos en casos de degeneración macular asociada a la edad de tipo exudativo00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=80682]], camposKey:0365-6691 2023-01-01 Protocol for the treatment of cystoid macular edema secondary to retinitis pigmentosa and other inherited retinal dystrophies Protocolo de tratamiento del edema macular quístico asociado a retinosis pigmentaria y otras distrofias hereditarias de la retina00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=75164]], camposKey:0030-3747 2022-12-01 Pathophysiology of Age-Related Macular Degeneration: Implications for Treatment615636, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=72043]], camposKey:0014-4835 2022-06-01 Hair cortisol level as a molecular biomarker in retinitis pigmentosa patients00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=75165]], camposKey:1170-229X 2022-05-01 Modifiable Determinants of Satisfaction with Intravitreal Treatment in Patients with Neovascular Age-Related Macular Degeneration355366, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=65211]], camposKey:1745-6673 2021-11-12 Long-term visual pathway alterations after elemental mercury poisoning: report of a series of 29 cases00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=65214]], camposKey:2045-2322 2021-01-12 Intraocular toxicity caused by MEROCTANE perfluorocarbon liquid00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=65213]], camposKey:1177-5483 2021-01-01 Descriptive Study of a Cohort of 488 Patients with Inherited Retinal Dystrophies10751084, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=59768]], camposKey:1673-5374 2021-01-01 Intravitreal stem cell paracrine properties as a potential neuroprotective therapy for retinal photoreceptor neurodegenerative diseases16311638, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=65212]], camposKey:0146-0404 2021-01-01 Phenotypic differences in the PRPH2 mutation in members of the same family assessed with OCT and OCTA00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=58381]], camposKey:1755-375X 2021-01-01 Silicone microbubbles after anti-vascular endothelial growth factor injections in patients with wet age-related macular degeneration: incidence, quantification and secondary optical coherence tomography artfacts00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=65215]], camposKey:2090-004X 2020-09-16 Early Detection of Incipient Retinal Pigment Epithelium Atrophy Overlying Drusen with Fundus Autofluorescencevs. Spectral Domain Optical Coherence Tomography00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56673]], camposKey:0721-832X 2020-06-20 Progression of myopic maculopathy in a Caucasian cohort of highly myopic patients with long follow-up: a multistate analysis00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=65216]], camposKey:0146-0404 2020-06-01 Influence of non-mydriasis on optical coherence tomography imaging quality in patients with Retinitis Pigmentosa00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=65217]], camposKey:0146-0404 2020-06-01 Is the new ISO 16672.2: 2019 the best prevention to avoid future cases of acute intraocular toxicity by perfluorocarbon liquids?00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=51256]], camposKey:0273-2300 2020-01-01 Chemical compounds causing severe acute toxicity in heavy liquids used for intraocular surgery1045270, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52553]], camposKey:1673-5374 2020-01-01 Intravitreal stem cell paracrine properties as a potential neuroprotective therapy for retinal photoreceptor neurodegenerative diseases16311638, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=66397]], camposKey:1661-6596 2020-01-01 Matrix metalloproteinases in age-related macular degeneration (Amd)132, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=63262]], camposKey:2073-4425 2020-01-01 PRPH2-Related Retinal Diseases: Broadening the Clinical Spectrum and Describing a New Mutation7730, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=50858]], camposKey:1120-6721 2020-01-01 Reliability of colour perimetry to assess macular pigment optical density in age-related macular degeneration14801486, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=43077]], camposKey:0007-1161 2019-01-01 Acute retinal toxicity associated with a mixture of perfluorooctane and perfluorohexyloctane: Failure of another indirect cytotoxicity analysis4954, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=43073]], camposKey:0146-0404 2019-01-01 Chemical considerations regarding the H-value methodology and its relation with toxicity determination33633364, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53048]], camposKey:0146-0404 2019-01-01 Clinical characteristics of proven acute intraocular toxicity by perfluorocarbon liquids (PFCL) used in retinal surgery00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53049]], camposKey:0146-0404 2019-01-01 Cytotoxicity evaluation of toxic substances identified in recent reported toxic lots of perfluorocarbon liquids used in intraocular surgery in patients00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=50859]], camposKey:0141-9382 2019-01-01 Development and evaluation of a head-mounted display system based on stereoscopic images and depth algorithms for patients with visual impairment4956, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53047]], camposKey:0146-0404 2019-01-01 Low Visual Pathway Alterations and Neurological Toxic Effects after Acute Mercury Poisoning in Zinc Manufacturer Workers00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53607]], camposKey:0275-004X 2018-04-01 Diagnostic and Therapeutic Challenges849853, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11666]], camposKey:2045-2322 2018-01-01 Comparison between direct contact and extract exposure methods for PFO cytotoxicity evaluation00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52974]], camposKey:0146-0404 2018-01-01 Toxicity of an endotamponade made by a mixture of perfluorooctane and perfluorohexyloctane evaluated by a new cytotoxicity method00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39306]], camposKey:0146-0404 2017-06-01 Acute retinal toxic damage by AlaOcta (R) a liquid perfluorooctane liquid used in retinal detachment surgery. Clinical picture and functional consequences00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10084]], camposKey:0275-004X 2017-01-01 Acute retinal damage after using a toxic perfluoro-octane for vitreo-retinal surgery11401151, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10088]], camposKey:1793-5458 2017-01-01 Control of disability glare by means of electrochromic filtering glasses: A pilot study00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10055]], camposKey:0950-222X 2017-01-01 Effectiveness and safety of nutritional supplements in the treatment of hereditary retinal dystrophies: a systematic review273285, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39307]], camposKey:0146-0404 2017-01-01 Perfluoro-n-octane cytotoxicity in human retinal pigment epithelial cell culture00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39308]], camposKey:0146-0404 2017-01-01 Perfluoro-n-octane cytoxicity in porcine neuroretina organotypic culture00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10063]], camposKey:1471-2415 2017-01-01 Predictive models of long-term anatomic outcome in age-related macular degeneration treated with as-needed Ranibizumab00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11667]], camposKey:0365-6691 2017-01-01 The acute toxicity problem with some perfluorooctanes El problema de la toxicidad aguda de algunos perfluoro-octanos455457, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52982]], camposKey:0022-3573 2016-01-01 Clinical Characterization and Frequency of Observation of Hereditary Retinal Diseases: Multicentric Study in Panama in 2012-2013618630, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10094]], camposKey:1046-6673 2016-01-01 Molecular Basis of Factor H R1210C Association with Ocular and Renal Diseases13051311, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52945]], camposKey:2167-8707 2016-01-01 Patient participation in the development of a clinical guideline for inherited retinal dystrophies691697, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10061]], camposKey:2167-8707 2016-01-01 Patient participation in the development of a clinical guideline for inherited retinal dystrophies (vol 4, pg 691, 2016)11, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10049]], camposKey:0030-3755 2016-01-01 Perfluorocarbon Liquids Toxicity: A Sanitary Alert6363, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39310]], camposKey:0146-0404 2016-01-01 PREDICTIVE MODELS OF LONG-TERM ANATOMIC OUTCOME IN EXUDATIVE AMD TREATED WITH AS-NEEDED RANIBIZUMAB00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10068]], camposKey:0146-0404 2016-01-01 Visual alterations in a cohort of young male patients with acute/subacute intoxication with mercury vapor00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10067]], camposKey:1471-2350 2016-01-01 X-Linked retinoschisis associated to a novel intragenic microdeletion: case report00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=49611]], camposKey:1755-375X 2015-01-01 BAX and BCL-2 polymorphisms, as predictors of proliferative vitreoretinopathy development in patients suffering retinal detachment: The Retina 4 project00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10093]], camposKey:2090-004X 2015-01-01 Loss of Visual Acuity after Successful Surgery for Macula-On Rhegmatogenous Retinal Detachment in a Prospective Multicentre Study00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10104]], camposKey:0007-1161 2015-01-01 Predicting proliferative vitreoretinopathy: temporal and external validation of models based on genetic and clinical variables4148, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10064]], camposKey:0146-0404 2015-01-01 PREDICTIVE FACTORS OF VISUAL IMPROVEMENT IN EXUDATIVE AMD PATIENTS AFTER 4 YEARS OF AS NEEDED RANIBIZUMAB TREATMENT00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39311]], camposKey:0146-0404 2015-01-01 WAVEFRONT ANALYSIS OF HIGHER-ORDER ABERRATIONS IN PATIENTS WITH HIGH MYOPIA00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10089]], camposKey:1471-2415 2014-01-01 Funduscopic results after 4-year follow-up treatment with ranibizumab for age-related macular degeneration in a region of Spain00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=49491]], camposKey:2168-6165 2014-01-01 Growth of geographic atrophy on fundus autofluorescence and polymorphisms of CFH, CFB, C3, FHR1-3, and ARMS2 in age-related macular degeneration528534, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10054]], camposKey:1471-2415 2014-01-01 Management of significant reactivation of old disciform scars in wet Age-Related Macular Degeneration00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53606]], camposKey:0146-0404 2013-06-01 Predictive Factors of Reading Performance Post Reading Rehabilitation Program in Central Field Loss Patients00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10103]], camposKey:0146-0404 2013-01-01 A Genetic Case-Control Study Confirms the Implication of SMAD7 and TNF Locus in the Development of Proliferative Vitreoretinopathy16651678, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10100]], camposKey:0030-3755 2013-01-01 A New Manual Retinal Thickness Measurement Protocol to Evaluate High Myopia Patients121125, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10048]], camposKey:2090-004X 2013-01-01 Autofluorescence Images with Carl Zeiss versus Topcon Eye Fundus Camera: A Comparative Study00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52946]], camposKey:0365-6691 2013-01-01 Evolucion clinica de pacientes con degeneracion macular asociada a la edad de tipo exudativo-hemorragico tratados con ranibizumab. Estudio Eye2Eye.
Clinical course of patients with exudative-haemorrhagic age-related macular degeneration treated with ranibizumab. Eye2Eye study.216222, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10098]], camposKey:0275-004X 2013-01-01 External validation of existing formulas to predict the risk of developing proliferative vitreoretinopathy: The retina 1 project; Report 515191527, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53046]], camposKey:1927-6990 2013-01-01 General Practitioners' knowledge gaps regarding Age Related Macular Degeneration and effectiveness of their e-learning training3747, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10083]], camposKey:0271-3683 2013-01-01 Ocular Pain After Intravitreal Injection278282, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10101]], camposKey:0161-6420 2013-01-01 The p53 Codon 72 Polymorphism (rs1042522) Is Associated with Proliferative Vitreoretinopathy The Retina 4 Project623628, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10102]], camposKey:1932-6203 2013-01-01 The T309G MDM2 Gene Polymorphism Is a Novel Risk Factor for Proliferative Vitreoretinopathy00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52947]], camposKey:0146-0404 2013-01-01 Visual loss in retinal detachment and macula-on after successful surgery, Retina 1 project00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10092]], camposKey:1120-6721 2012-01-01 A propensity score matching application: indications and results of adding scleral buckle to vitrectomy: The Retina 1 Project: Report 3244253, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10066]], camposKey:0308-0110 2012-01-01 E-learning strategies to improve general practitioners' knowledge of age-related macular degeneration517518, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10085]], camposKey:0030-3755 2012-01-01 Pathology Associated with Optical Coherence Tomography Macular Bending due to either Dome-Shaped Macula or Inferior Staphyloma in Myopic Patients712, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10095]], camposKey:0146-0404 2012-01-01 Relevance of Complement Factor H-Related 1 (CFHR1) Genotypes in Age-Related Macular Degeneration10871094, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10077]], camposKey:0030-3755 2012-01-01 Retinal Pigment Epithelium Tears in Age-Related Macular Degeneration Treated with Antiangiogenic Drugs: A Controlled Study with Long Follow-Up7883, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53608]], camposKey:0065-2598 2012-01-01 SJOGREN-LARSSON SYNDROME344350, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53050]], camposKey:0146-0404 2012-01-01 The Impact Of Low Vision In The Activities Of Daily Living And Emotional State Of Elderly People00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52969]], camposKey:2090-5688 2012-01-01 Variations in Functional and Anatomical Outcomes and in Proliferative Vitreoretinopathy Rate along a Prospective Collaborative Study on Primary Rhegmatogenous Retinal Detachments: The Retina 1 Project-Report 4.00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10097]], camposKey:1755-375X 2011-01-01 Genetic association study of age-related macular degeneration in the Spanish population00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=49502]], camposKey:0365-6691 2011-01-01 Genetics and ARMD: from the laboratory to the consulting room101102, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10086]], camposKey:0161-6420 2011-01-01 Sjogren-Larsson Syndrome21012102, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11669]], camposKey:1177-5467 2011-01-01 Training and professional profile of retinologists in Spain: Retina 2 project, Report 4483490, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10096]], camposKey:0161-6420 2010-01-01 A Strong Genetic Association between the Tumor Necrosis Factor Locus and Proliferative Vitreoretinopathy: The Retina 4 Project24172423, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=40837]], camposKey:1938-2375 2010-01-01 Benign fleck retinal findings on multifocal ERG, microperimetry, and OCT.00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=50860]], camposKey:1560-2133 2010-01-01 Choroidal neovascularisation in punctate inner choroidopathy: therapeutic options.1928, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11670]], camposKey:0275-004X 2010-01-01 Diagnostic and therapeutic challenges13111315, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10058]], camposKey:1120-6721 2010-01-01 PRPH2 (Peripherin/RDS) mutations associated with different macular dystrophies in a Spanish population: a new mutation724732, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53051]], camposKey:0146-0404 2009-01-01 Development of Electrochromic Filters for Visual Rehabilitation00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11671]], camposKey:0365-6691 2009-01-01 Formación y actividad clínica de los retinólogos en españa: Un primer acercamiento. Proyecto retina 2. Análisis descriptivo Training and clinical activity of Spanish retinologists: A preliminary approach. Retina 2 project. Descriptive analysis7584, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53604]], camposKey:0275-004X 2008-07-01 Diagnostic and therapeutic challenges10181022, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53052]], camposKey:0146-0404 2008-01-01 Analysis of Peripherin-rds in Isolated Cases and Spanish Families Presenting Different Macular Dystrophies00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53042]], camposKey:0146-0404 2008-01-01 Anatomical and Functional Outcomes After Surgery for Primary Rhegmatogenous Retinal Detachments (RD) in Phakic and Pseudophakic Patients. Preliminary Results of a Multicentric Prospective Study: The Retina 1 Project52405240, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10082]], camposKey:0300-7995 2008-01-01 Burden of illness of bilateral neovascular age-related macular degeneration in Spain21032111, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10072]], camposKey:0275-004X 2008-01-01 Diagnostic and therapeutic challenges174179, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10069]], camposKey:0007-1161 2008-01-01 Non-complicated retinal detachment management: variations in 4 years. Retina 1 project; report 1523525, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52967]], camposKey:1935-1089 2008-01-01 Oct findings in torpedo maculopathy109111, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10090]], camposKey:0007-1161 2008-01-01 Surgical outcomes for primary rhegmatogenous retinal detachments in phakic and pseudophakic patients: the Retina 1 Project - report 2378382, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53053]], camposKey:0146-0404 2008-01-01 Training Reading Performance Might Improve Depression in Low Vision Patients00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10070]], camposKey:1542-8877 2007-01-01 Atypical myopic retinoschisis157159, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11673]], camposKey:0161-6420 2007-01-01 Complement Factor H00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53605]], camposKey:0161-6420 2007-01-01 Complement factor H193193, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=58179]], camposKey:0365-6691 2007-01-01 El impacto de la Ley de Dependencia en los pacientes con baja visión393394, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10081]], camposKey:0927-3948 2007-01-01 Photodynamic therapy for subfoveal and juxtafoveal choroidal neovascularization associated with punctate inner choroidopathy2729, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53041]], camposKey:0146-0404 2007-01-01 Telephone Satisfaction Questionnaire for Evaluation the Efficacy of a Vision Rehabilitation Treatment35593559, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11672]], camposKey:0365-6691 2007-01-01 The impact of the dependency law in low vision patients El impacto de la ley de dependencia en los pacientes con baja visión393394, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10091]], camposKey:0030-3747 2006-01-01 Intraretinal immunohistochemistry findings in proliferative vitreoretinopathy with retinal shortening193200, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10099]], camposKey:1395-3907 2006-01-01 Photodynamic therapy in subfoveal and juxtafoveal idiopathic and postinflammatory choroidal neovascularization743748, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=58180]], camposKey:0365-6691 2005-01-01 Monocromatismo de conos azules ligado a X: Una familia afecta3540, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11674]], camposKey:0531-5131 2005-01-01 Reading comparative study: Electronic vs. conventional devices8587, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11675]], camposKey:0365-6691 2005-01-01 X-linked blue cone monochromatism. A familial case report Monocromatismo de conos azules ligado a X. Una familia afecta.3540, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11676]], camposKey:0365-6691 2004-01-01 Corneal epithelial complications after vitrectomy: a retrospective study Complicaciones corneales epiteliales de las vitrectomías: estudio retrospectivo.155161, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56674]], camposKey:0146-0404 2003-05-01 Clinical and surgical features of retinal shortening: The most severe and less recognized form of proliferative vitreoretinopathy (PVR)00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10075]], camposKey:0146-0404 2003-01-01 Clinical and surgical features of retinal shortening: The most severe and less recognized form of proliferative vitreoretinopathy (PVR)29790, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11677]], camposKey:0365-6691 2003-01-01 Retinal shortening: the most severe form of proliferative vitreoretinopathy (PVR). Acortamiento retiniano: la forma más grave de la vitreorretinopatía proliferante (VRP).653657, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=13961]], camposKey:0365-6691 2003-01-01 Roturas retinianas iatrogénicas en las vitrectomías: estudio retrospectivo487491, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10087]], camposKey:1059-7794 2002-01-01 Analysis of ABCA4 in Mixed Spanish Families Segregating Different Retinal Dystrophies00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11679]], camposKey:0365-6691 2002-01-01 Functional improvement after vision rehabilitation in low monocular vision after myopic macular degeneration and retinal detachment Mejora funcional tras la rehabilitación visual en una paciente con visión monocular deficitaria debido a degeneración macular miópica y desprendimiento de retina.9598, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10071]], camposKey:0002-9394 2002-01-01 Fundus autofluorescence in patients with age-related macular degeneration and high risk of visual loss341349, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=44578]], camposKey:0365-6691 2002-01-01 Mejora funcional tras la rehabilitación visual en una paciente con visión monocular deficitaria debido a degeneración macular miópica y desprendimiento de retina9597, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10079]], camposKey:1018-4813 2002-01-01 Mutation and haplotype analysis of ABCA4 in mixed Spanish families and implication of this gene in a pattern dystrophy phenotype.237237, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=8812]], camposKey:0146-0404 2002-01-01 Study of the efficacy of a new electronic device for the ARMD: A new therapeutic option00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11680]], camposKey:0365-6691 2001-01-01 First results of the IOBA low vision unit Primeros resultados de la Unidad de Baja Visión del IOBA.719722, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39313]], camposKey:0146-0404 2001-01-01 Fundus autofluorescence in patients with age-related macular degeneration and high risk characteristics.00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=67278]], camposKey:0365-6691 2000-01-01 Comentarios sobre el artículo titulado «Fotocoagulación en rejilla en la degeneración macular asociada a la edad (DMAE). Primeros resultados»213214, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=40839]], camposKey:0365-6691 2000-01-01 Comments on Grid photocoagulation in age-related macular degeneration (ARMD). Preliminary results Comentarios sobre el artículo titulado: Fotocoagulación en rejilla en la degeneración macular asociada a la edad (DMAE). Primeros resultados.213214, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11681]], camposKey:0002-9297 2000-01-01 Further evidence for an association of ABCR alleles with age-related macular degeneration487491, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10057]], camposKey:1080-7683 2000-01-01 Pharmacokinetics of 0.5 mg of a single and a multiple dose of intravitreal vancomycin in infected rabbit eyes373381, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10078]], camposKey:0146-0404 2000-01-01 The degree of symmetry of fundus autofluorescence in early age-related maculopathy.00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10073]], camposKey:1080-7683 1998-01-01 Pharmacokinetics of intravitreal vancomycin in normal and infected rabbit eyes555563, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10074]], camposKey:0146-0404 1997-01-01 Changes in fundus autofluorescence in age related maculopathy using cSLO in patients in a laser photocoagulation trial00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10059]], camposKey:0146-0404 1997-01-01 Efficacy of a new regime of intravitreal vancomycin in the treatment of endophthalmitis rabbit eyes51975197, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=71301]], camposKey:0146-0404 1996-02-15 Pharmacokinetics of a multiple regimen of 0.5 mg of vancomycin in endophthalmic rabbit eyes35733573, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=43956]], camposKey:0365-6691 1996-01-01 Estudio citológico del vítreo en las vitrectomías: diferencias entre vitreorretinopatía proliferante y retinopatía diabática proliferante197204, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=1892]], camposKey:0021-9673 1996-01-01 High-performance liquid chromatographic determination of vancomycin in rabbit serum, vitreous and aqueous humour after intravitreal injection of the drug231238, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=40841]], camposKey:0146-0404 1996-01-01 Pharmacokinetics of a multiple regimen of 0.5 mg of vancomycin in endophthalmic rabbit eyes00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39314]], camposKey:0146-0404 1995-01-01 DISTRIBUTION OF AGE-RELATED LENS OPACITIES IN A SPANISH POPULATION-SAMPLE00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39317]], camposKey:0146-0404 1995-01-01 INTRAVITREAL PHARMACOKINETICS OF 0.5 AND 1 MG OF VANCOMYCIN IN ENDOPHTHALMIC RABBIT EYES00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10062]], camposKey:0146-0404 1995-01-01 VALUE OF VITREOUS CYTOLOGY IN THE DIAGNOSIS OF VITREORETINAL DISEASES00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10052]], camposKey:0146-0404 1995-01-01 Vitreous levels of lomefloxacin after intravenous injection in the rabbit. Sample extraction with a perfused rabbit eye model00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10060]], camposKey:0146-0404 1994-01-01 PHARMACOKINETICS OF INTRAVITREAL VANCOMYCIN IN INFECTED AND UNINFECTED RABBIT EYES19071907][CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=11089]},camposKey: 97 103 Calidad de vida y efectos psicosociales en baja visión 8498358493Manual de Baja Visión y Rehabilitación Visual 1 null Editorial Médica Panamericana , CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=22172]},camposKey: 3 8 Concepto de baja visión, discapacidad visual y rehabilitación visual: profesionales de la visión 8498358493Manual de Baja Visión y Rehabilitación Visual 1 null Editorial Médica Panamericana , CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=3605]},camposKey: 3 8 Concepto de baja visión, discapacidad visual y rehabilitación visual.
Profesionales de la visión 8498358493Manual de Baja Visión y Rehabilitación Visual 1 null Editorial Médica Panamericana , CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=19151]},camposKey: 179 185 Enfermedades hereditarias difusas de los fotoreceptores 978-84-9113-564-7Manual de retina SERV 2 2019-01-01 Elsevier España, CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=19670]},camposKey: 460 470 Capítulo 25. Cirugía Vitreorretiniana en los traumatismos oculares. Sección 25E. Tamponadores, manipuladores y tinciones en la cirugía del traumatismo ocular 978-84-89085-68-8Traumatología ocular 1 2018-01-01 Sociedad Española de Oftalmología, CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=19669]},camposKey: 97 99 Endoftalmitis luética en paciente con implante intravítreo de dexametasona 978-84-16269-41-9Casos clínicos en oftalmología II: Problemas diagnósticos en patología retinocoroidea 1 2018-01-01 Euromedice Vivactis, CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=19153]},camposKey: 158 163 Distrofias Retinianas 8490221529Manual de retina 1 2013-03-01 Elsevier , CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=31170]},camposKey: 161 163 Enfermedades hereditarias difusas de los fotorreceptores: Distrofias progesivas de conos y distrofias progresivas de conos y bastones 8490221529Manual de retina 1 2013-03-01 Elsevier , CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=31169]},camposKey: 158 161 Enfermedades hereditarias difusas de los fotorreceptores: Retinitis pigmentosa 8490221529Manual de retina 1 2013-03-01 Elsevier , CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=19155]},camposKey: 89 94 Estudios descriptivos 978-84-89085-51-0De la idea a la publicación científica. Manual de investigación clínica 1 2013-01-01 MacLine, CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=19109]},camposKey: 687 718 New electro-optic and display technology for visually disabled people 9781466639867Handbook of Research on ICTs for Human-Centered Healthcare and Social Care Services 1 2013-01-01 Medical Information Science Reference, CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=19158]},camposKey: 337 356 Distrofias maculares 978-84-89085-44-2PATOLOGÍA Y CIRUGÍA DE LA MÁCULA 1 2010-01-01 Sociedad Española de Oftalmología, CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=19157]},camposKey: 319 335 Enfermedades Hereditarias de los Conos 978-84-89085-44-2PATOLOGÍA Y CIRUGÍA DE LA MÁCULA 1 2010-01-01 Sociedad Española de Oftalmología, CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=26004]},camposKey: 816 817 Mejora en la calidad de vida de personas deficientes visuales mediante rehabilitación visual 8481961442Apoyos, autodeterminación y calidad de vida 1 2001-01-01 Amarú ][][Llibres{id=com.sigma.fs3.argos.domain.gpc.GpcLlibresPK[ifcactivitat=LLI, ifccomptador=101733],camposKey=978-84-9835-849-0Manual de baja visión y rehabilitación visual 1 2015-01-01 Editorial Médica Panamericana}][][][][][com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=62094]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=62894]]][com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=62094]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=62894]]][][][com.sigma.fs3.argos.domain.gpc.GpcTesis[id=com.sigma.fs3.argos.domain.gpc.GpcTesisPK[ifcactivitat=TES, ifccomptador=2145638966]], com.sigma.fs3.argos.domain.gpc.GpcTesis[id=com.sigma.fs3.argos.domain.gpc.GpcTesisPK[ifcactivitat=TES, ifccomptador=2145638169]], com.sigma.fs3.argos.domain.gpc.GpcTesis[id=com.sigma.fs3.argos.domain.gpc.GpcTesisPK[ifcactivitat=TES, ifccomptador=2145640539]], com.sigma.fs3.argos.domain.gpc.GpcTesis[id=com.sigma.fs3.argos.domain.gpc.GpcTesisPK[ifcactivitat=TES, ifccomptador=2145636997]]][][][][][][][][com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@1a8a5c0d][][com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63df61, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63ddd8, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63df08, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63ded4, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63d514, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63d513, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63d54e, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@3bf147, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63eb81, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63d754, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63d6d7, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@3751e6, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63eb8c, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e6df, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63ebe5, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63d67b, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e025, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e288, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e0f4, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e68a, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e8c0, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e895, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e1b5, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e045, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e171, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e6b2, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e837, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e041, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e869, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@373664, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63dfef, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e61a, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e809, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e038, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e56b, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e11d, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e91c, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e381, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@373689, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@373a70, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e59d, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e36b, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@373aab, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63d8b9, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e4f6, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e2ee, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e32b, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63ebb3, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e44c, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e511, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e510, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63d933, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63ea8e, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63db7b, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e2c9, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63ead3, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63da95, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63de8e, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63de8f, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e6c4, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e512, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@372257][][][com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.commons.ArgosPK[act=ESF, cont=60884]]][com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.commons.ArgosPK[act=ESF, cont=60884]]][][com.sigma.fs3.argos.domain.gpc.GpcPatents[id=com.sigma.fs3.argos.domain.gpc.GpcPatentsPK[ifcactivitat=PAT, ifccomptador=1005]], com.sigma.fs3.argos.domain.gpc.GpcPatents[id=com.sigma.fs3.argos.domain.gpc.GpcPatentsPK[ifcactivitat=PAT, ifccomptador=1154]]][][com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@465521], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@46595b], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@4662cc], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@467c00], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@45eee8], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@467c25], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@45eea9], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@414d42], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5c29ab], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@413397], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@41335c], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5c294d], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@45eeaa], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@45eeab], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@413bdc], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@4136a9], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@45eeac], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5c28fe], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@460794], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@41235e], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@45f45f]][][CatedrasConvenios{id=22, codigoPersona=com.sigma.fs3.argos.domain.gpc.PersonalGPC[ifcidPers=23489], codigoTipo=CAT, codigoContable=null, titulo=CÁTEDRA ZEISS EN LA UNIVERSIDAD DE VALLADOLID, fechaInicio=2017-09-01, fechaFin=null, importe=12100.0, visiblePortal=1, visibleCvn=1, visibleMemoria=1, validado=S}][][][][com.sigma.fs3.argos.domain.gpc.altres.ProjecteInnovacio@1581e, com.sigma.fs3.argos.domain.gpc.altres.ProjecteInnovacio@155c3, com.sigma.fs3.argos.domain.gpc.altres.ProjecteInnovacio@1531c, com.sigma.fs3.argos.domain.gpc.altres.ProjecteInnovacio@142e2, com.sigma.fs3.argos.domain.gpc.altres.ProjecteInnovacio@14803, com.sigma.fs3.argos.domain.gpc.altres.ProjecteInnovacio@1480d][]
